MedTrace Logo

Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)

NCT03248089 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2019-01-09

No results posted yet for this study

Summary

Tumor Derived cell free DNA (cfDNA) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known. The primary objective of this study is to demonstrate the non-inferiority of cfDNA-based versus tumor tissue-based genotyping.

Conditions

Interventions

DIAGNOSTIC_TEST

Guardant360

Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.

Sponsors & Collaborators

  • Guardant Health, Inc.

    collaborator INDUSTRY

  • MedSIR

    lead OTHER

Principal Investigators

  • Rafael Rosell · IOR

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-07-31
Completion
2019-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03248089 on ClinicalTrials.gov